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Bullous pemphigoid (BP) is an autoimmune skin-blistering
disease characterized by the presence of autoantibodies against
the hemidesmosomal proteins BP230 and BP180. In the IgG
passive transfer mouse model of BP, subepidermal blistering is
triggered by anti-BP180 antibodies and depends on the comple-
ment system, mast cell (MC) degranulation, and neutrophil
infiltration. In this study, we have identified the signaling events
that connect the activation of the complement system and MC
degranulation. We found that mice deficient in MCs or the C5a
receptor (C5aR) injected with pathogenic anti-BP180 IgG failed
to develop subepidermal blisters and exhibited a drastic reduc-
tion in p38 MAPK phosphorylation compared with WT mice.
Local reconstitutionwithMCs fromWTbut not C5aR-deficient
mice restored high levels of p38 MAPK phosphorylation and
subepidermal blistering inMC-deficientmice. Local injectionof
recombinantC5a inducedphosphorylationof p38MAPK inWT
but not MC-deficient mice. Cultured mouse MCs treated with
recombinant C5a exhibited a significant increase in p38 MAPK
phosphorylation and MC degranulation. Taken together, these
data demonstrate that C5a interacts with C5aR on MCs and
that this C5a-C5aR interaction triggers activation of the p38
MAPK pathway, subsequent MC degranulation, and ultimately
BP blistering.
Bullous pemphigoid (BP)3 is an acquired autoimmune skin-
blistering disease characterized by the presence of circulating
and tissue-bound autoantibodies against two major hemides-
mosomal proteins, BP230 (BPAG1) and BP180 (BPAG2 or type
XVII collagen) (1–11). These anti-hemidesmosomal autoanti-
bodies, along with complement components, are deposited
along the basement membrane at the dermal-epidermal junc-
tion of perilesional skin (12–14). Basal keratinocytes detach
from the underlying dermis, leading to blister formation (5).
Using an animal model of BP in which neonatal BALB/c mice
are injected with anti-murine BP180 antibodies, we previously
demonstrated that dermal-epidermal separation is triggered by
anti-BP180 IgG and depends on complement activation, mast
cells (MCs), and neutrophils (PMNs) (15–17). The binding of
pathogenic IgG to BP180 activates the classical pathway of the
complement and leads to MC degranulation, PMN recruit-
ment, and subsequent skin blistering (18).However, the cellular
processes linking complement activation and MC degranula-
tion are not defined in BP.
Complement activation via the classical, alternative, and lec-
tin pathways generates the anaphylotoxin C5a (19). A potent
chemoattractant and inflammatory mediator, C5a acts on a
wide range of myeloid and lymphoid lineage cells, including
skin MCs (20, 21). Skin MCs express the C5a receptor (C5aR;
CD88) (22), and interaction of C5a and C5aR induces MC
degranulation and the release of proinflammatory cytokines
such as IL-1, IL-6, TNF-, and GM-CSF (23). In PMNs and
monocytes, the interaction of C5a and C5aR leads to activation
of p38 MAPK (24–26). p38 MAPK is a key signaling molecule
involved in translating extracellular environmental conditions,
particularly inflammatory conditions, into cellular responses
(27, 28). MC activation via antigen cross-linking of surface IgE
molecules leads to p38 MAPK activation and cytokine release
(29); however, p38MAPK activation upon engagement of C5aR
on MCs has not yet been reported.
In this work, we examined the role of C5a-C5aR interaction
in the progression of experimental BP. We found that C5a
interactswithC5aRonMCs and that thisC5a-C5aR interaction
triggers activation of the p38 MAPK pathway and ultimately
induces MC degranulation and subsequent BP blistering.
EXPERIMENTAL PROCEDURES
Materials—The p38 MAPK inhibitor SB203580 and the
inactive analog SB202474 were purchased from Calbiochem.
Rabbit anti-phospho-p38MAPK antibody was purchased from
Cell Signaling (Danvers, MA), and rabbit anti-p38 MAPK anti-
body was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Recombinant C5a was purchased from R&D Sys-
tems (Minneapolis, MN). Protein concentration was deter-
mined with the RCDC protein assay (Bio-Rad). The ECLWest-
ern blot analysis kit was purchased from GE Healthcare.
Laboratory Animals—Breeding pairs of C57BL/6J, C4-defi-
cient (C4/), MC-deficient WBB6F1-KitW/KitW-v (MC/),
andC5aR-deficient (C5aR/)micewere purchased from Jack-
son ImmunoResearch Laboratories (Bar Harbor, ME) and
maintained at the University of North Carolina at Chapel Hill.
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The MC deficiency in KitW/KitW-v mice is caused by distinct
mutations in MC c-Kit (30). Neonatal mice (24–36 h old with
bodyweights between 1.4 and 1.6 g)were used for passive trans-
fer experiments. All animal care and animal experiments were
approved by the University of North Carolina Animal Care
Committee andwere in accordancewith theNational Institutes
of Health guidelines.
Preparation of Pathogenic anti-BP180 IgG—The preparation
of recombinant murine BP180 and the immunization of New
ZealandWhite rabbits were performed as described previously
(31–33). The pathogenicity of these IgG preparations was
tested by passive transfer experiment as described below. A
pathogenic anti-murine BP180 IgG preparation (R621) and a
control IgG preparation were used in this study (17).
Induction of Experimental BP and Clinical Evaluation of
Animals—Neonates were given on the back one intradermal
injection of a sterile solution of IgG in PBS (50 l of IgG, 2.5
mg of IgG/g of body weight) as described previously (31).
The skin at the IgG injection site of the mice from the test
and control groups was examined at different time points
after the IgG injection. The extent of cutaneous disease was
scored as follows: , no detectable skin disease; 1, mild
erythematous reaction with no evidence of the epidermal
detachment sign (this sign was elicited by gentle friction of
the mouse skin, which, when positive, produced fine persis-
tent wrinkling of the epidermis); 2, intense erythema and
epidermal detachment sign involving 10–50% of the epider-
mis in localized areas; and 3, intense erythema with frank
epidermal detachment sign involving 50% of the epidermis
in the injection site.
After clinical examination, the animals were killed, and skin
and serum specimens were obtained. Skin sections were used
for (a) routine histological examination by light microscopy
(hematoxylin/eosin staining) to localize the lesional site and
PMN infiltration, (b) toluidine blue staining to quantify MCs
and MC degranulation, (c) direct immunofluorescence assays
to detect rabbit IgG and mouse C3 deposition at the basement
membrane zone (BMZ), and (d) myeloperoxidase (MPO) enzy-
matic assay to quantify the PMNaccumulation at the skin injec-
tion site described below. The sera of injected animals were
tested by indirect immunofluorescence techniques to deter-
mine the titers of rabbit anti-murine BP180 antibodies using
mouse skin cryosections as the substrate. Direct and indirect
immunofluorescence studies were performed as described pre-
viously (31) using commercially available FITC-conjugated
goat anti-rabbit IgG (Kirkegaard & Perry Laboratories, Inc.).
Monospecific goat anti-mouse C3 IgG was purchased from
Cappel Laboratories, Inc.
Quantification of PMNAccumulation at the Skin Site—MPO
activity in skin sites of the injected animals was assayed as a
measure of PMN infiltration as described (34, 35). A stan-
dard reference curve was established using purified MPO
(Athens Research and Technology, Inc., Athens, GA). The
skin samples were extracted by homogenization in extrac-
tion buffer containing 0.1 M Tris-Cl (pH 7.6), 0.15 M NaCl,
and 0.5% hexadecyltrimethylammonium bromide. MPO
activity in the supernatant fraction was measured by the
change in absorbance at 460 nm resulting from decomposi-
tion of H2O2 in the presence of o-dianisidine. MPO content
was expressed as units of MPO activity/mg of protein. Pro-
tein concentrations were determined by the Bio-Rad dye
binding assay using BSA as a standard.
Determination of C5a Levels in Skin—Skin from the IgG
injection site of the diseased and control mice was mechan-
ically homogenized in PBS to extract proteins. The level of
mouse C5a in the skin was measured by ELISA (R&D Sys-
tems). Microtiter plates were coated with rat anti-mouse
C5a antibody, incubated with skin protein extracts followed
by goat anti-mouse C5a detection antibody, developed, and
read at A492 nm. The C5a level was expressed as A492 nm read-
ing/mg of protein.
Quantification of MCs and MC Degranulation—MCs and
MCdegranulation in skin sampleswere quantified according to
Wershil et al. (36) with modification. Briefly, lesional and non-
lesional skin sections of IgG-injected mice were fixed in 10%
formalin. Paraffin sections (5 m thick) were prepared and
stained with toluidine blue and hematoxylin/eosin. The total
number of MCs was counted and classified as degranulated
(10% of the granules exhibiting fusion or discharge) or nor-
mal in five fields under a light microscope as described pre-
viously (15, 36). The results are expressed as a percentage of
MC degranulation.
MCReconstitution—KitW/KitW-vmice were repaired of their
MC deficiency selectively and locally by the injection of growth
factor-dependent bone marrow-derived culturedMCs into the
skin (15, 37, 38). Briefly, femoral bone marrow cells from WT
and C5aR/ mice were maintained in vitro for 4 weeks in
RPMI 1640 complete medium (Invitrogen) supplemented with
20% WEHI-3-conditioned medium until MCs represented
95% of the total cells as determined by toluidine blue staining
and flow cytometry analysis using antibodies specific for the
mast cell-surface markers Fc receptor I, c-Kit, and CD13 (37).
Murine IgE and rat anti-mouse IgE were purchased from
Southern Biotechnology Associates (Birmingham, AL). FITC-
labeled rat anti-mouse c-Kit and FITC-labeled rat anti-mouse
CD13 were obtained from Pharmingen. MCs (1  106 in 20 l
of medium) were injected intradermally into the ears of 8–10-
week-old MC-deficient mice. Medium alone (20 l) was
injected intradermally into the ears ofMC/ andMC/mice
to serve as negative controls. This procedure selectively and
locally reconstitutes the dermal MC population without sys-
temic effects (38).MCreconstitutionwas confirmedby staining
skin sections from MC-injected sites with toluidine blue. Ten
weeks after the adoptive transfer of MCs, when the injected
MCswere fullymatured into functional cutaneousMCs (15, 37,
38), both ears of the mice were injected intradermally with
pathogenic anti-BP180 IgG (2 mg/20 l/site). Twenty-four
hours later, ear skin biopsies were obtained and analyzed by
hematoxylin/eosin and toluidine blue staining and MPO enzy-
matic assay as described above.
In Vivo and in Vitro Inhibition of p38MAPKActivation—For
the in vivo inhibitor studies, mice were pretreated with 50 l of
the p38MAPK inhibitor SB203580 or inactive analog SB202474
(intradermal, 10 g/g of body weight). Two hours later, the
mice were injected intradermally with 50 l of pathogenic IgG
or control IgG (2.5 mg/g of body weight), and the mice were
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examined at different time points for BP skin lesions and p38
MAPK activation (see below). For in vitro inhibitor studies,
cultured bone marrow-derivedMCs from C57BL/6J mice were
incubated with C5a (25 ng/ml) in the presence of the p38
MAPK inhibitor SB203580 (20 M) for 0–60 min, and cell
extracts were assayed for p38 MAPK activation.
Detection of Total and Phospho-p38 MAPKs—Protein was
extracted from skin samples in lysis buffer (8 M urea, 4%
CHAPS, 2.5 mM dithiothreitol, 40 mM Tris, 10 M pepstatin,
100 M leupeptin, 10 M E-64, 1 mM phenylmethylsulfonyl
fluoride, 0.1 M sodium orthovanadate, 0.5 mM sodium fluoride,
and 0.5 M okadaic acid). For the cell culture studies, bone
marrow-derived MCs were incubated with a buffer control or
C5a (25 ng/ml) in the absence or presence of SB203580 (20 M)
for 0–60 min at 37 °C. The cells were harvested and lysed on
ice, and 20 g of each protein extract was loaded onto a 10%
acrylamide gel and separated by SDS-PAGE. Gels were trans-
ferred to PVDF membranes (Millipore) and probed by immu-
noblotting for total and phospho-p38 MAPKs. Western blots
were developed by ECL reaction (Amersham Biosciences). The
signal intensity was quantified by scanning chemiluminescence
on aGeneGnome scanner (SyngeneUSA, Frederick,MD) using
GeneSnap software.
Statistical Analysis—Data are expressed as means S.E. and
were analyzed using paired Student’s t test. A p value0.05was
considered significant.
RESULTS
Mice Lacking the Classical Pathway of the Complement Sys-
tem Are Resistant to Experimental BP and Exhibit a Reduced
Level of Skin C5a—We previously reported that the classical
pathway of complement activation is critical to the pathogene-
sis of experimental BP in mice (18). Wild-type mice (C4/)
andmice deficient in the alternative pathway component factor
B (Fb/) developed subepidermal blisters following injection
with pathogenic anti-murine BP180 IgG; however, mice defi-
cient in the classical pathway component C4 (C4/) were
resistant to blister formation (Fig. 1A and Table 1). Twenty-
four hours following injection, C4/ mice had significantly
lower levels of C5a present in the skin compared with WT and
Fb/ mice (p  0.0001) (Fig. 1B). Significantly fewer infiltrat-
ing PMNswere present in the skin of theC4/mice compared
with theWT or Fb/ mice, as determined by quantification of
MPO enzymatic activity (Fig. 1C). These results demonstrate
that complement activation via the classical pathway is essen-
tial for generation of C5a, recruitment of PMNs to the skin, and
blistering in experimental BP.
Mice Lacking C5aR Are Resistant to Experimental BP and
Exhibit Impairment in MC Degranulation and p38 MAPK
Activation—C5a fragments act primarily through binding to
C5aR (CD88) (39). Having determined that high levels of C5a
are present in the skin of mice susceptible to experimental BP,
FIGURE 1. Levels of C5a in the skin are significantly reduced in pathogenic IgG-injected mice lacking the classical pathway of complement. Neonatal
WT (C4/), C4-deficient (C4/), and factor B-deficient (Fb/) mice were injected intradermally with pathogenic rabbit anti-murine BP180 IgG R621 or
control rabbit IgG (2.5 mg/g of body weight). The injected animals were examined 24 h post-injection. A, hematoxylin/eosin-stained skin sections from these
mice showed a subepidermal vesicle with neutrophilic infiltrate in the pathogenic IgG-injected C4/ (left panel) and Fb/ (right panel) mice. In contrast,
R621-injected C4/ mice showed no evidence of subepidermal vesiculation at the light microscopic level (middle panel). E, epidermis; D, dermis; V, vesicle.
Images are 125 magnified. B, a C5a-specific ELISA assay exhibited significantly reduced levels of C5a in the skin of C4/ mice compared with the diseased
mice (*, p  0.0001; bar 4 versus bars 2 and 6). C, MPO enzymatic assay of skin protein extracts revealed a significantly lower number of infiltrating PMNs in the
C4/ mice compared with the diseased mice (*, p  0.001; bar 4 versus bars 2 and 6). n  eight for each group. Three independent experiments were done for
each group of mice.
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we next examined the role of C5aR in disease development.We
injected C5aR-deficient mice (C5aR/) and WT mice
(C5aR/) with pathogenic anti-BP180 antibodies and found
that C5aR/ mice developed blisters, but C5aR/ mice did
not (Fig. 2A and Table 1). Although C5aR/ mice failed to
develop skin lesions, the amount of C5a present in their skin
was comparable with that in theWTmice at 4 h post-IgG injec-
tion (Fig. 2B), when the early phase of PMN infiltration begins
(17). These data demonstrate that C5aR deficiency does not
affect C5a generation. However, MC activation in the skin of
the pathogenic IgG-injected C5aR/ mice was severely
impaired as evidenced by toluidine blue staining, aMC-specific
histochemical staining.At 2 hpost-injection,whenMCdegran-
ulation triggered by pathogenic IgG reaches its peak in experi-
mental BP (15), extensive MC degranulation was observed in
the dermis of WT mice (Fig. 2C, left panel). In contrast,
C5aR/ mice exhibited a minimal level of MC degranulation
in the dermis (Fig. 2C, right panel). We quantified MC degran-
ulation and found a significant reduction in the number of
degranulatingMCs in C5aR/ mice compared withWTmice
(p  0.001) (Fig. 2D). BecauseMC degranulation releases cyto-
kines that recruit PMNs to the skin during experimental BP
pathogenesis (15), we hypothesized that the C5aR/ mice
would be unable to effectively attract PMNs to the skin. Indeed,
the pathogenic IgG-injected C5aR/ mice showed a signifi-
cantly reduced PMN infiltration in the skin compared with the
diseased WT mice (Fig. 2E).
In addition to the lack of MC activation, C5aR/ mice
injected with pathogenic antibodies also lacked activation of
p38 MAPK, a critical signaling pathway in inflammation and
autoimmunity (28). By immunoblotting, the lesional skin of the
pathogenic IgG-injected WT mice exhibited a much more
intense phosphorylated p38 MAPK band compared with the
skin of the pathogenic IgG-injected C5aR/ mice (Fig. 3A,
lane 2 versus lane 4). Quantitative analysis of the intensity of
each band on the immunoblots confirmed that the phospho-
p38MAPK levels in the lesional skin of the C5aR/ mice were
significantly higher than those in the C5aR/ mice (p 
0.0001) (Fig. 3B, bar 2 versus bar 4). These results suggest that
the molecular interaction between C5a and C5aR leads to MC
activation and p38 MAPK signaling, followed subsequently by
PMN recruitment and BP blistering.
p38 MAPK Activation Is Required for Experimental BP—To
determine whether p38MAPK activation is involved in the dis-
ease development or is simply a secondary stress response, neo-
natal WT mice were pretreated with the p38 MAPK inhibitor
SB203580 or inactive control SB202474 (intradermal, 10 g/g
of body weight). Two hours later, the mice were injected intra-
dermally with pathogenic antibodies. The SB202474-treated
mice developed clinical and histological subepidermal blisters
with IgG deposition at the BMZ (Fig. 4A, left panels, and Table
1). However, SB203580 treatment completely abolished the BP
skin lesions (Fig. 4A, right panels). Mice pretreated with
SB202474 exhibited significantly higher levels of p38 MAPK
phosphorylation at 2 and 24 h post-IgG injection (Fig. 4B, lanes
2 and 5) than mice pretreated with SB203580 (lanes 3 and 6).
Inhibition of p38MAPK activation also resulted in significantly
reduced MC degranulation (Fig. 4C, bar 4 versus bar 3) and
FIGURE 2. Mice lacking C5aR are resistant to experimental BP. Neonatal
WT (C5aR/) and C5aR-deficient (C5aR/) mice were injected intrader-
mally with pathogenic rabbit anti-murine BP180 IgG R621 or control rabbit
IgG (2.5 mg/g of body weight). The injected animals were examined 2, 4, and
24 h post-injection. A, pathogenic IgG R621-induced BP blisters in C5aR/
mice (left panel) but not in C5aR/ mice (right panel) at 24 h post-injection.
B, a C5a-specific ELISA assay showed no difference in skin C5a levels between
C5aR/ and C5aR/ mice at 4 h post-IgG injection (p  0.325; bar 2 versus
bar 4). C, toluidine blue staining showed an extensive MC degranulation in the
C5aR/ mice (left panel) at 2 h post-IgG injection, whereas the C5aR/ mice
(right panel) exhibited a minimal level of MC degranulation. D, quantification
of degranulated MCs on the toluidine blue-stained skin sections showed a
drastically increased MC degranulation in the C5aR/ mice compared with
the C5aR/ mice (*, p  0.001; bar 2 versus bar 4). E, MPO enzymatic assay of
skin protein extracts revealed a significantly lower number of infiltrating
PMNs in the C5aR/ mice compared with the diseased mice (*, p  0.001; bar
2 versus bar 4). n  eight for each group. Three independent experiments
were done for each group of mice.
TABLE 1
Role of C5aR and p38 MAPK in experimental BP
Neonatal WT, C4/, Fb/, and C5aR/ mice were injected intradermally with
either control IgG R50 or pathogenic rabbit anti-mBP180 IgG R621 alone (2.5 mg/g
of body weight) or pretreated with the p38 MAPK inhibitor SB203580 or inactive
control SB202474 (10 g/g of body weight). All mice were examined 24 h after IgG
injection. The extent of cutaneous disease was scored as follows: , no detectable
skin disease; 1, mild erythematous reaction with no evidence of the epidermal
detachment sign (this sign was elicited by gentle friction of the mouse skin, which,
when positive, produced fine persistent wrinkling of the epidermis); 2, intense
erythema and epidermal detachment sign involving 10–50% of the epidermis in
localized areas; and 3, intense erythema with frank epidermal detachment sign
involving 50% of the epidermis in the injection site. The clinical disease severity is







R50 16 0.00  0.00
R621 22 2.66  0.36
R621 SB203580 6 0.33  0.11
R621 SB202474 6 2.75  0.17
C4/
R50 8 0.00  0.00
R621 8 0.19  0.09
Fb/
R50 8 0.00  0.00
R621 8 2.56  0.15
C5aR/
R50 8 0.00  0.00
R621 8 0.25  0.09
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PMN infiltration (Fig. 4D, bar 4 versus bar 3). These results
demonstrate that p38 MAPK is critical for MC activation and
the subsequent development of experimental BP.
C5aR-mediated p38 MAPK Activation Depends on MCs—
The complement system and MC activation are indispensable
to the pathogenesis of experimental BP (18, 40). Having dem-
onstrated that p38MAPK activation is also required for disease
development, we next investigated the links between comple-
ment, MCs, and p38 MAPK. MCs express C5aR and can be
activated by C5a (41), so we reasoned that the interaction of
C5a with MC C5aR may trigger p38 MAPK signaling. To test
this hypothesis, we injected neonatal MC-sufficient (MC/)
andMC-deficient (MC/)mice with PBS or recombinant C5a
(rC5a; intradermal, 50 ng in PBS/mouse) and analyzed phos-
phorylated p38 MAPK levels in the skin at the injection sites.
We observed a significantly higher level of p38 MAPK activa-
tion in the rC5a-treated MC/ mice (Fig. 5A, lane 2) com-
pared with the rC5a-treated MC/ mice (lane 4). In vitro, we
found that bone marrow-derived MCs, when incubated with
rC5a (25 ng/ml) for as little as 5min, exhibited high levels of p38
MAPK activation (Fig. 5B). The addition of SB203580 (20 M)
to MC culture prior to rC5a treatment almost completely
blocked p38 MAPK activation (Fig. 5C). These data strongly
suggest that p38 MAPK activation occurs in MCs following
exposure to C5a.
C5aR is broadly expressed across a number of cell types, and
p38 MAPK is activated in many immune cells in response to
extracellular inflammatory signals (42, 43). To strengthen the
evidence that MCs are the key cell type that interact with C5a
and promote development of experimental BP, we reconsti-
tutedMC/ mice withMCs fromC5aR/ mice or withMCs
from C5aR/ mice. If p38 MAPK activation is dependent on
C5aR on MCs, then MC/ mice reconstituted with MCs
expressing C5aR should be susceptible to experimental BP, but
mice reconstituted with C5aR-deficient MCs should be pro-
tected from experimental BP. To test this hypothesis, we
injected the left ears of MC/ mice with C5aR/ MCs and
the right ears of the sameMC/micewithC5aR/MCs (1
106 cells/site). Ten weeks later, both ears of the mice were
injected intradermally with pathogenic anti-BP180 IgG (2
mg/20 l/site) and examined 24 h post-IgG injection. Similar
numbers of MCs were present in the C5aR/ MC-reconsti-
tuted ears and the C5aR/ MC-reconstituted ears. MC/
mice thatwere not reconstitutedwith anyMCs andmice recon-
stituted with C5aR/ MCs developed no skin lesions, whereas
FIGURE 3. Mice lacking C5aR show impaired p38 MAPK activation
induced by pathogenic antibodies. Neonatal WT (C5aR/) and C5aR-defi-
cient (C5aR/) mice were injected intradermally with pathogenic rabbit
anti-murine BP180 IgG R621 or control rabbit IgG (2.5 mg/g of body weight).
The skin protein extracts of injected animals were examined 24 h post-injec-
tion by immunoblotting for p38 MAPK activation. A, immunoblot analysis of
p38 MAPK activation. Skin protein extracts (30 g/lane) were analyzed by
immunoblotting with antibodies against phosphorylated p38 MAPK (Phos-
pho-p38) and total p38 MAPK (Total p38). A much more intense band for phos-
pho-p38 MAPK was seen in the skin of the diseased C5aR/ mice (lane 2)
compared with the C5aR/ mice (lane 4). B, quantification of p38 MAPK
activation. The intensity of each band on the immunoblots was quantified
with a GeneGnome scanner and GeneSnap software. The phospho-p38
MAPK levels in the skin of the C5aR/ mice were significantly higher com-
pared with the C5aR/ mice (*, p  0.0001; bar 2 versus bar 4). n  eight for
each group. Three independent experiments were done for each group of
mice.
FIGURE 4. Blocking p38 MAPK activation abolishes experimental BP. Neo-
natal C57BL/6J mice were intradermally administered the p38 MAPK inhibitor
SB203580 or inactive control SB202474 (10 g/g of body weight). Two hours
later, the mice were injected intradermally with pathogenic rabbit anti-mu-
rine BP180 IgG R621 or control rabbit IgG (2.5 mg/g of body weight). The
injected animals were examined at different time points post-IgG injection.
A, mice pretreated with the inactive control SB202474 prior to injection with
pathogenic antibodies developed BP clinically and histologically, with IgG
deposition at the BMZ (left panels). In contrast, inhibition of p38 MAPK with
SB203580 completely abolished the skin lesions clinically and histologically,
without interference with IgG deposition at the BMZ (right panels). Arrows
indicate basal keratinocytes. E, epidermis; D, dermis; V, vesicle. B, immunoblot
analysis of p38 MAPK activation. Pathogenic antibodies induced high levels
of phospho-p38 MAPK in SB202474-treated mice at 2 and 24 h (lanes 2 and 5),
whereas SB203580 treatment induced only background levels of p38 MAPK
phosphorylation (lanes 3 and 6). C, quantification of MC degranulation. Pre-
treatment with SB203580 (bar 4) significantly reduced MC degranulation at
2 h post-pathogenic IgG injection compared with PBS (bar 2) or SB202474
pretreatment (bar 3) (*, p  0.001; bar 4 versus bars 2 and 3). D, quantification
of MPO activity revealed significantly lower levels of PMN infiltration in the
SB203580-treated mice (bar 4) compared with the SB202474-treated mice
(bar 3) at 24 h post-IgG injection (*, p  0.01). n  six for each group. Three
independent experiments were done for each group of mice.
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MC/mice reconstitutedwithC5aR/MCs showed subepi-
dermal blistering (Fig. 6A). The number of infiltrating PMNs in
the C5aR/ MC-reconstituted site was significantly higher
than that in the C5aR/ MC-reconstituted site (Fig. 6B, bar 6
versus bar 5). Pretreatment with the p38 MAPK inhibitor
SB203580 abolished BP skin lesions (Fig. 6A, fourth panel) and
markedly reduced PMN infiltration in the MC/ mice recon-
stituted with C5aR/ MCs (Fig. 6B, bar 7). Taken together,
these results demonstrate that disease progression is depen-
dent on MCs expressing C5aR and p38 MAPK activation.
DISCUSSION
Activation of the classical pathway of complement generates
C5a, amolecule critical for tissue inflammation and the recruit-
ment of PMNs to the cutaneous BMZ. C5a may carry out this
role either directly (by functioning as a PMN chemoattractant
itself) or indirectly (by stimulating local cells to release proin-
flammatory mediators such as IL-8) or through a combination
of these two mechanisms (44). In experimental BP, we found
that C5a contributes to disease progression primarily through
interaction with C5aR on MCs, as evidenced by the failure of
C5aR/ mice to induce MC degranulation and subsequent
PMN accumulation upon passive transfer of pathogenic anti-
BP180 antibodies.
Without C5aR, activation of p38 MAPK in the pathogenic
anti-murine BP180 IgG-injected mouse skin is impaired. p38
MAPK is an important signaling molecule involved in translat-
ing extracellular environmental conditions into cellular re-
sponses (27, 28). This signaling pathway plays a key role in
numerous immune and inflammatory diseases, including rheu-
matoid arthritis and the autoimmune skin disease pemphigus
vulgaris (45–47). Our data show that p38 MAPK activation is
not a secondary stress response and instead is required for
experimental BP, asmice treatedwith p38MAPK inhibitors are
protected from disease progression.
FIGURE 5. C5a activates p38 MAPK of MCs in vivo and in vitro. A, C5a acti-
vates MC p38 MAPK in vivo. MC-sufficient (MC/) and MC-deficient (MC/)
mice were injected intradermally with PBS or C5a (50 ng in 50 l of PBS/
mouse), and the skin extracts were examined 4 h later by immunoblotting
with antibodies to phospho-p38 MAPK and total p38 MAPK. Significantly
higher levels of phospho-p38 MAPK were seen in the C5a-injected MC/
mice (lane 2) than in the PBS control (lane 1) and C5a-injected MC/ (lane 4)
mice. n  six for each group. Two independent experiments were done for
each group of mice. B, C5a activates MC p38 MAPK in vitro. Bone marrow-
derived MCs from C57BL/6J mice were incubated with a buffer control (lane 1)
or C5a (25 ng/ml; lanes 2– 4) for 0 – 60 min, and cell extracts were assayed for
p38 MAPK activation. All C5a-treated MCs showed high levels of phospho-
p38 MAPK. C, SB203580 blocks C5a-induced MC p38 MAPK phosphorylation
in vitro. Bone marrow-derived MCs from C57BL/6J mice were incubated with
a buffer control (lane 1) or C5a (25 ng/ml; lanes 2– 4) in the presence of the p38
MAPK inhibitor SB203580 (20 M) for 0 – 60 min, and cell extracts were
assayed for p38 MAPK activation. SB203580 treatment almost completely
blocked p38 MAPK activation. A representative of three independent exper-
iments is shown.
FIGURE 6. MC reconstitution restores BP in MC-deficient mice. Pathogenic
antibodies were injected into the ears of MC/ and MC/ mice reconsti-
tuted with 1  106 MCs from C5aR/ mice and MC/ mice reconstituted
with MCs from C5aR/ mice with or without pretreatment with SB203580.
The ears were examined 24 h post-IgG injection. A, hematoxylin/eosin stain-
ing showed that MC/ and MC/ mice reconstituted with WT MCs devel-
oped dermal-epidermal junction separation following antibody injection.
MC/ mice reconstituted with C5aR/ MCs and MC/ mice reconstituted
with C5aR/ MCs that were pretreated with SB203580 prior to antibody
injection failed to develop dermal-epidermal junction separation. B, quanti-
fication of PMN infiltration. Pathogenic antibodies induced BP with signifi-
cantly increased PMN infiltration in MC/ mice (bar 2) and MC/ mice
reconstituted WT MCs (bar 6) but not in MC/ mice reconstituted with
C5aR/ MCs (bar 5) and MC/ mice reconstituted with WT MCs plus
SB203580 (bar 7). *, p  0.01 (six mice/group). Three independent experi-
ments were done for each group of mice.
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It has been reported that in PMNs and monocytes, interac-
tion of C5a andC5aR leads to activation of p38MAPK (24–26).
In this study, we have provided direct evidence that MCs also
use the same pathway of C5a-C5aR-mediated p38 MAPK acti-
vation. WT mice injected with rC5a exhibited significantly
greater p38 MAPK phosphorylation than MC/ mice, indi-
cating that MCs are a key source of the p38 MAPK signaling
required for induction of experimental BP. Compellingly, we
found that MC/ mice reconstituted with MCs expressing
C5aR prior to passive transfer of pathogenic antibody devel-
oped blisters; however, mice reconstituted with MCs lacking
C5aR expression did not exhibit blister formation. Further-
more, rC5a directly activated p38MAPK inC5aR-sufficient but
not C5aR-deficient cultured MCs. Taken together, these data
demonstrate that C5a interaction with C5aR on MCs and the
subsequent MC p38 MAPK activation are indispensible for
development of experimental BP. In summary, these studies
identify the C5a-C5aR interaction as being a critical molecular
linker between basal keratinocyte-based complement activa-
tion and MC-based p38 MAPK activation in experimental BP.
Activation of p38 MAPK is essential for MC activation, PMN
infiltration, and blister formation in experimental BP.
Inhibitors of p38MAPKare currently under investigation for
treatment of autoimmune and inflammatory diseases (48–50).
We found that BP patients have significantly elevated levels of
p38 MAPK activation in lesional skin, indicating that p38
MAPK is likely an important mediator of inflammation in the
human as well as the mouse. Thus, treatment of BP with these
p38 MAPK inhibitors may prove to be a practical therapy if
specific and safe inhibitors can be developed.
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(2009)Mol. Immunol. 46, 2753–2766
43. Ono, K., and Han, J. (2000) Cell. Signal. 12, 1–13
44. Müller-Eberhard, H. J. (1988) Annu. Rev. Biochem. 57, 321–347
45. Berkowitz, P., Hu, P., Liu, Z., Diaz, L. A., Enghild, J. J., Chua, M. P., and
Rubenstein, D. S. (2005) J. Biol. Chem. 280, 23778–23784
46. Berkowitz, P., Hu, P., Warren, S., Liu, Z., Diaz, L. A., and Rubenstein, D. S.
(2006) Proc. Natl. Acad. Sci. U.S.A. 103, 12855–12860
47. Schett, G., Zwerina, J., and Firestein, G. (2008) Ann. Rheum. Dis. 67,
909–916
48. Adcock, I. M., Chung, K. F., Caramori, G., and Ito, K. (2006) Eur. J. Phar-
macol. 533, 118–132
49. Perez, O. A., and Patton, T. (2009) Drugs Aging 26, 833–846
50. Cohen, P. (2009) Curr. Opin. Cell Biol. 21, 317–324
Mast Cell C5a Receptor Required for Bullous Pemphigoid
APRIL 29, 2011 • VOLUME 286 • NUMBER 17 JOURNAL OF BIOLOGICAL CHEMISTRY 15009
